We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
THE LEE COMPANY

Download Mobile App




Novel Biomarker-Based Tests to Predict Response to Drugs for Treatment of Chronic Kidney Disease

By LabMedica International staff writers
Posted on 30 Jan 2023
Print article
Image: KidneyIntelX provides risk assessment for rapid progressive decline in kidney function in stages 1-3b (Photo courtesy of Renalytix)
Image: KidneyIntelX provides risk assessment for rapid progressive decline in kidney function in stages 1-3b (Photo courtesy of Renalytix)

Kidney disease affects over 850 million people globally. According to estimates by the Centers for Disease Control and Prevention estimates, 15% of U.S. adults, or about 37 million people, suffer from chronic kidney disease (CKD). Almost 95% of people with CKD are in the early stages of the disease. Despite its magnitude, early-stage (1-3) CKD still remains underdiagnosed and undertreated, mainly due to its asymptomatic nature at this time in the disease. It is estimated that as many as 9 out of 10 adults with CKD, and about 2 out of 5 adults with severe CKD are unaware that they have the condition. Now, a consortium of industry, academic and clinical research leaders aims to change that by developing personalized drug response tests in CKD.

Renalytix plc (London, UK) has announced the launch of PRIME-CKD, a consortium of industry, academic and clinical research leaders, which aims to validate and implement in clinical practice, novel biomarker-based tests that predict response to existing drugs used by patients diagnosed with CKD. PRIME-CKD is funded by Horizon Europe, the European Union’s key funding program for research and innovation. The project has a total budget of USD 10 million over a projected five-year period with approximately 10% of the budget set aside for commercial translation activities to be undertaken by Renalytix.

The consortium brings together leading experts from 11 academic institutions, along with partners from patient representative foundations and regulatory agencies. The PRIME-CKD consortium will focus on demonstrating the utility of novel biomarkers as tools to enable better selection of drug therapies for patients, for use in daily clinical practice as well as clinical trials. If some of the biomarkers are successful, then the PRIME-CKD program will seek their qualification through the European Medicines Agency and the U.S. FDA for this purpose. The PRIME-CKD program builds on breakthrough findings in the Innovative Medicine Initiative 2 program BEAt-DKD initiated in 2016 that identified novel biomarkers of disease progression and treatment response in patients with diabetic kidney disease. The project is expected to benefit from Renalytix’s expertise in biomarker research translation and existing intellectual property on urinary Epidermal Growth Factor (uEGF) for which the company enjoys exclusive access.

The project is closely aligned with Renalytix’s objective of expanding the clinical utility of the KidneyIntelX platform beyond prognosis to prediction and monitoring of drug response. KidneyIntelX is a laboratory developed test which has shown to be a reliable, bioprognostic methodology that yields a simple-to-understand, custom risk score, enabling prediction of which adult patients with T2D and early CKD (stages 1-3) are at low, intermediate or high risk for a rapid progressive decline in kidney function. By combining information from KidneyIntelX with newer cardio- and reno-protective therapies, physicians will gain access to more information for determining which patients are at higher or lower risk for rapid disease progression. Based on the information, physicians could then target resources and guideline-recommended treatments to advance kidney health in a more appropriate manner. KidneyIntelX has shown a 72% improvement in identifying patients at a high risk for rapid progressive decline in kidney function versus the current standard of care (eGFR and UACR).

“Results from this project are expected to translate into significant patient benefits and decreased societal costs associated with CKD by helping ensure that patients receive the most effective therapy, at the right time, to slow or prevent the kidney failure requiring dialysis or transplant,” said Hiddo J.L Heerspink, the program coordinator from the University Medical Center Groningen, Netherlands.

“The opportunity to participate in the PRIME-CKD program combined with ongoing development of novel biomarkers from our collaboration with Joslin Diabetes Center and planned data generation in completed clinical studies expected in 2023, further strengthens KidneyIntelX as a precision medicine platform in CKD,” added Fergus Fleming, Chief Technology Officer of Renalytix who will serve on the steering committee for PRIME-CKD and lead the implementation of the research outputs into clinical practice.

Related Links:
Renalytix plc

Platinum Supplier
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Gold Supplier
Foam Tipped Applicator
PurSwab 5"
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Silver Supplier
Vitamin D Test
Quick Profile Vitamin D

Print article

Channels

Clinical Chemistry

view channel
Image: A module with eight micro-devices, complete with microfluidic channels and drive motors (Photo courtesy of U.S Department of Energy)

Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses

Understanding the acidity or alkalinity of substances through pH measurement is crucial in many fields, from environmental monitoring to healthcare product safety. In many cases, these measurements must... Read more

Hematology

view channel
Image: The QScout hematology analyzer has received US FDA 510(k) clearance (Photo courtesy of Ad Astra Diagnostics)

First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC

Sepsis, a critical medical condition that arises as an extreme response to infection, poses a significant health threat. It occurs when an infection triggers a widespread inflammatory response in the body.... Read more

Immunology

view channel
Image: PointCheck is the world’s first device for non-invasive white cell monitoring (Photo courtesy of Leuko Labs)

World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw

One of the toughest challenges for cancer patients undergoing chemotherapy is experiencing a low count of white blood cells, also known as neutropenia. These cells play a crucial role in warding off infections.... Read more

Microbiology

view channel
Image: Current testing methods for antibiotic susceptibility rely on growing bacterial colonies in the presence of antibiotics (Photo courtesy of 123RF)

Rapid Antimicrobial Susceptibility Test Returns Results within 30 Minutes

In 2019, antimicrobial resistance (AMR) was responsible for the deaths of approximately 1.3 million individuals. The conventional approach for testing antimicrobial susceptibility involves cultivating... Read more

Pathology

view channel
Image: AI methods used in satellite imaging can help researchers analyze tumor images (Photo courtesy of Karolinska Institutet)

AI Approach Combines Satellite Imaging and Ecology Techniques for Analysis of Tumor Tissue

Advancements in tumor imaging technology have significantly enhanced our ability to observe the minute details of tumors, but this also brings the challenge of interpreting vast amounts of data generated... Read more

Technology

view channel
Image: A new electrochemical device can quickly and inexpensively identify people at greatest risk for osteoporosis (Photo courtesy of ACS Central Science, 2023)

Electrochemical Device Identifies People at Higher Risk for Osteoporosis Using Single Blood Drop

With the global increase in life expectancy, the incidence of age-related conditions like osteoporosis is increasing. Osteoporosis, affecting around 200 million individuals worldwide, has a higher incidence... Read more

Industry

view channel
Image: The acquisition significantly expands Medix Biochemica’s portfolio of IVD raw materials (Photo courtesy of ViroStat)

Medix Biochemica Acquires US-Based ViroStat to Expand Infectious Diseases Antibody Offering

Medix Biochemica (Espoo, Finland), a supplier of critical raw materials to the in vitro diagnostics (IVD) industry, has acquired ViroStat LLC (Portland, ME, USA), a provider of infectious disease antibodies... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.